Related Companies
|
[]
|
||||||||
Related Funds
|
[]
|
||||||||
English
|
|||||||||
oda_NewBusinessRelationAbstract|
|
|
||||||||
oda_UpdateAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
oda_CorrectionAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
oda_DateOfThePreviousNotificationAboutTheSameSubject|
|
|
-
|
|||||||
oda_DelayedAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
oda_AnnouncementContentSection|
|
|
||||||||
oda_NatureOfTheOtherPartyWithWhichNewBusinessRelationWillStart|
|
|
Tedarikçi (Supplier)
|
|||||||
oda_NameSurnameOrCompanyTitleOfCustomerOrSupplier|
|
|
Moderna Switzerland GMBH
|
|||||||
oda_IfExistsShareOfCustomerOrSupplierInNetSalesOrCostOfGoodsSoldOnLatestDisclosedProfitOrLossAndOtherComprehensiveIncomeStatementOfCompany|
|
|
-
|
|||||||
oda_IfExistsShareOfCustomerOrSupplierInTradeReceivablesOrDebtsOnLatestDisclosedStatementofFinancialPositionOfCompany|
|
|
-
|
|||||||
oda_ExpectedStartingDateOfNewBusinessRelation|
|
|
-
|
|||||||
oda_IfExistSignificantProvisionsOfTheContractTextBlock|
|
|
Detailed Below.
|
|||||||
oda_ImpactOfNewBusinessRelationOnCompanyActivities|
|
|
Positive Impact is Expected
|
|||||||
oda_ExplanationSection|
|
|
||||||||
oda_ExplanationTextBlock|
|
-Unofficial Translation- GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. ("GEN") has signed with MODERNA SWITZERLAND GMBH, located at Aeschenvorstadt 48, 4051 Basel, Switzerland ("MODERNA") LOCAL REPRESENTATIVE AND SERVICES AGREEMENT on 13 May 2022, with regard to the product developed by MODERNA, mRNA-1273, which is a novel lipid nanoparticle (LNP) encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized spike (S) protein of SARS-CoV-2 ("the Vaccine"). Under the LOCAL REPRESENTATIVE AND SERVICES AGREEMENT, GEN will act as MODERNA's exclusive local service provider and representative in Turkey to assist MODERNA in facilitating business with respect to the possible supply of the Vaccine in Turkey. |
We proclaim that our above disclosure is in conformity with the principles set down in “Material Events Communiqué” of Capital Markets Board, and it fully reflects all information coming to our knowledge on the subject matter thereof, and it is in conformity with our books, records and documents, and all reasonable efforts have been shown by our Company in order to obtain all information fully and accurately about the subject matter thereof, and we’re personally liable for the disclosures.